Skip to main navigation Presentations Earnings Presentations Q3 2021 Biogen Earnings Presentation Oct 20, 2021 Q2 2021 Biogen Earnings Presentation Jul 22, 2021 Q1 2021 Biogen Earnings Presentation Apr 22, 2021 Q4 and Full Year 2020 Biogen Earnings Presentation Feb 03, 2021 Q3 2020 Biogen Earnings Presentation Oct 21, 2020 Investor R&D Day 2021 Biogen 2021 Investor R&D Day Sep 21, 2021 Biogen Digital Health Sep 21, 2021 Advancements in Research Sep 21, 2021 Biogen Gene Therapy Sep 21, 2021 Alzheimer’s Disease Research Portfolio Sep 21, 2021 Biomarkers Sep 21, 2021 Biotherapeutics and Medicinal Sciences at Biogen Sep 21, 2021 Human Genetics Sep 21, 2021 Movement Disorders at Biogen Sep 21, 2021 MS Portfolio Sep 21, 2021 Conference and Other Investor Presentations Biogen ADUHELM Launch Jun 08, 2021 J.P. Morgan 39th Annual Healthcare Conference Jan 11, 2021 Aducanumab Update Presentation Oct 22, 2019 Biogen ALS & R&D Portfolio Webcast Presentation Jun 05, 2019 Biogen Planned Acquisition of Nightstar Therapeutics Mar 04, 2019 Biogen MS & R&D Webcast Presentation Dec 12, 2018 Biogen on R&D Progress Targeting Stroke Jun 28, 2018 Medical and Scientific Conference Presentations Dose and time dependent changes in plasma ptau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials at CTAD Nov 11, 2021 View Presentation Baseline EMBARK data from EMERGE, ENGAGE, and PRIME participants in the EMBARK re-dosing study at CTAD Nov 09, 2021 View Presentation Results from the Phase 3 VALOR study and its open-label extension at ANA 2021 View Presentation Oct 17, 2021 View Presentation ICARE AD-US: Design of a Prospective, Single-arm, Multicenter, Noninterventional Real-world Study of Aducanumab in United States Jul 29, 2021 View Presentation 🔈 Listen to Audio Reduction in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline Jul 26, 2021 View Presentation 🔈 Listen to Audio Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Patients with Early Alzheimer’s Disease Jul 26, 2021 View Presentation 🔈 Listen to Audio Considerations for the Real-World Management of ARIA from the Aducanumab Phase 3 Studies EMERGE and ENGAGE Jul 26, 2021 View Presentation 🔈 Listen to Audio Item-level Analysis of Clinical Measures in Patients with Early Symptomatic Alzheimer’s Disease Following Treatment with High-Dose Aducanumab in the Phase 3 Study EMERGE Jul 26, 2021 View Presentation 🔈 Listen to Audio Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Lumbar Intrathecal Bolus Administrations of Antisense Oligonucleotide (ISIS 814907; BIIB080) Targeting Tau mRNA in Patients with Mild Alzheimer’s Disease Jul 26, 2021 View Presentation 🔈 Listen to Audio Aducanumab EMBARK study design poster at AAN 2021 Apr 17, 2021 View Presentation Aducanumab EMBARK study design audio presentation at AAN 2021 Apr 17, 2021 Listen to Audio Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD Mar 13, 2021 View Presentation Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD Mar 13, 2021 View Presentation Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Mar 10, 2021 View Presentation Aducanumab data review with Global Alzheimer's Platform Foundation Feb 23, 2021 View Presentation Aducanumab data review and Q&A with Alzheimer's Disease International Jan 14, 2021 View Presentation Aducanumab EMBARK study design at CTAD 2020 Nov 04, 2020 View Presentation Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation) Sep 23, 2020 View Presentation Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation) Sep 19, 2020 View Presentation A Biogen Perspective on Drug Development for Neurological Diseases: The Example of Alzheimer’s Disease Aug 31, 2020 View Presentation Aducanumab Phase 3 Topline Results at AAIC (encore virtual presentation) Jul 29, 2020 View Presentation Aducanumab Phase 3 Topline Results at AAN (encore virtual presentation) May 18, 2020 View Presentation Aducanumab Phase 3 Topline Results at AAT-AD/PD (encore presentation) Apr 02, 2020 View Presentation Aducanumab Phase 3 Topline Results at CTAD Dec 05, 2019 View Presentation Safety, PK, PD, and Exploratory Efficacy in Single and Multiple Dose Study of a SOD1 Antisense Oligonucleotide (BIIB067) Administered to Participants With ALS May 07, 2019 View Presentation CTAD Oral Presentation: Aducanumab Titration Dosing Regimen: 36-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease Oct 26, 2018 View Presentation CTAD Keynote: What Have We Learned from Aducanumab? Oct 25, 2018 View Presentation Cumulative Aducanumab Safety Data from PRIME: A Randomized, Double-blind, Placebo-controlled, Phase 1b Study Oct 24, 2018 View Presentation Aducanumab 48-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease Oct 24, 2018 View Presentation 24-Month Analysis of APOE ε4 Carriers in PRIME, a Randomized Phase 1B Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab Jul 22, 2018 View Presentation 24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab Jul 22, 2018 View Presentation Aducanumab Titration Dosing Regimen: 24-Month Interim Analysis from PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease Apr 22, 2018 View Presentation Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease Apr 22, 2018 View Presentation The Importance of Early Identification and Treatment of Alzheimer’s Disease Mar 15, 2018 View Presentation NUSINERSEN CHERISH Final Results (Poster & Presentation) Ph3 AAN 2017 Apr 25, 2017 Source AAN, April 25, 2017 View Presentation NUSINERSEN NURTURE Interim Results (Presentation) Ph3 AAN 2017 Apr 25, 2017 Source AAN, April 25, 2017 View Presentation NUSINERSEN ENDEAR Final Results (Presentation) Ph3 AAN 2017 Apr 24, 2017 Source AAN, April 24, 2017 View Presentation Annual Stockholder Presentation Biogen Annual Stockholder Presentation 2021 June 2, 2021 Hemophilia Spin-off Presentations Bioverativ (BIVV) Analyst Day Presentation January 6, 2017 Hemophilia Spin-off Presentation May 3, 2016 Tools Print Page Stockholder Communications E-mail Alerts FAQs Footer Links Investors Careers News Releases Our Stories Receive Our Updates Contact Us Follow us: Legal Community Guidelines Cookie Policy Forward-Looking Statement Notice to CA Residents Privacy Policy Terms & Conditions © 2021 Biogen